Fluciclovine (18F) PET/CT in biochemicAL reCurrence Of Prostate caNcer
Status:
Completed
Trial end date:
2018-06-22
Target enrollment:
Participant gender:
Summary
The main aim is to assess the impact of using 18F-fluciclovine (as a PET imaging radiotracer)
on the clinical and treatment decision required for managing patients with biochemically
recurrent prostate cancer (BCR) who are being considered for salvage treatment with the
intention of providing disease cure. Also, this study will consolidate the information
regarding diagnostic performance of fluciclovine PET/CT in a large number of prospectively
followed patients at several centres in the UK and assess the effect of PSA level on the
likelihood of detecting cancer lesions by 18F-fluciclovine
Phase:
Phase 3
Details
Lead Sponsor:
Blue Earth Diagnostics
Collaborators:
IND 2 Results LLC Innovate UK Syne Qua Non Limited